Disease Domain | Count |
---|---|
Nervous System Diseases | 2 |
Endocrinology and Metabolic Disease | 1 |
Immune System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 2 |
Top 5 Target | Count |
---|---|
Mitochondrial proteins x Proton pump | 1 |
BDNF x Mitochondrial proteins | 1 |
Mechanism Mitochondrial proteins stimulants [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Mechanism BDNF modulators [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date02 Jul 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
MP-101(Mitochon Pharmaceuticals) ( Mitochondrial proteins x Proton pump ) | Amyotrophic Lateral Sclerosis More | Phase 2 |
MP-201 ( BDNF x Mitochondrial proteins ) | Optic Neuritis More | Preclinical |
MP-301 | Nonalcoholic Steatohepatitis More | Discontinued |